# Elevance Health vs Regeneron Pharmaceuticals

URL: https://funkfolio.com/compare/elv-vs-regn

> Elevance Health ($93.8B, P/E 18.4) and Regeneron Pharmaceuticals ($99.1B, P/E 21.2) compared: size, valuation, margins, debt, cash and price change.

---

## Elevance Health vs Regeneron Pharmaceuticals

Elevance Health (ELV), health care, and Regeneron Pharmaceuticals (REGN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Regeneron Pharmaceuticals is worth $99.1B on the stock market and Elevance Health $93.8B: Regeneron Pharmaceuticals is valued at 6% more. Elevance Health trades at 18.4 times earnings and Regeneron Pharmaceuticals at 21.2; operating margins in their latest fiscal years were 3.62% and 24.9%. Over the past year Elevance Health's share price has moved +37.5% and Regeneron Pharmaceuticals's +31.3%.

### Key facts

- **Elevance Health market value:** $93.8B
- **Regeneron Pharmaceuticals market value:** $99.1B
- **Elevance Health P/E:** 18.4
- **Regeneron Pharmaceuticals P/E:** 21.2
- **Elevance Health revenue:** $199.1B FY to 2025-12-31
- **Regeneron Pharmaceuticals revenue:** $14.3B FY to 2025-12-31
- **Superinvestors holding both:** 3

Market values as of 18 Nov 2026, 02:34 UTC.

Elevance Health vs Regeneron Pharmaceuticals: every measure side by side

| Measure | Elevance Health | Regeneron Pharmaceuticals |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $93.8B lower | $99.1B higher |
| Revenue | $199.1B higher | $14.3B lower |
| Earnings | $5.7B higher | $4.5B lower |
| Employees | 96,129 higher | 15,410 lower |
| Total assets | $121.5B higher | $40.6B lower |
| Valuation |  |  |
| P/E | 18.4 lower | 21.2 higher |
| P/S | 0.5 lower | 6.9 higher |
| P/B | 2.1 lower | 2.9 higher |
| Dividend yield | 1.54% higher | 0.39% lower |
| Profitability |  |  |
| Operating margin | 3.62% lower | 24.9% higher |
| Balance sheet |  |  |
| Net assets | $43.9B higher | $31.3B lower |
| Total liabilities | $77.5B higher | $9.3B lower |
| Total debt | $32B higher | $2B lower |
| Cash on hand | $9.5B higher | $3.1B lower |
| Price change |  |  |
| Today | -2.77% lower | +0.56% higher |
| 1 year | +37.5% higher | +31.3% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Elevance Health 131.1, Regeneron Pharmaceuticals 136.0.

- Elevance Health (ELV)
- Regeneron Pharmaceuticals (REGN)

Elevance Health and Regeneron Pharmaceuticals share prices over one year, rebased to 100: Elevance Health ends at 131.1, Regeneron Pharmaceuticals at 136.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | ELV | REGN |
| --- | --- | --- |
| Nov 28, 2025 | 102.2 | 110.8 |
| Dec 31, 2025 | 105.9 | 109.6 |
| Jan 30, 2026 | 104.5 | 105.3 |
| Feb 27, 2026 | 96.7 | 111.0 |
| Mar 31, 2026 | 88.5 | 109.7 |
| Apr 30, 2026 | 113.8 | 100.4 |
| May 29, 2026 | 118.8 | 87.3 |
| Jun 30, 2026 | 116.9 | 88.5 |
| Jul 31, 2026 | 113.6 | 108.3 |
| Aug 31, 2026 | 118.6 | 113.5 |
| Sep 30, 2026 | 117.5 | 107.7 |
| Oct 30, 2026 | 126.9 | 131.7 |
| Nov 17, 2026 | 131.1 | 136.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (3)

- [Harry Burn](https://funkfolio.com/gurus/harry-burn) 2.0% / 3.0%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 1.4% / 0.1%
- [Jim Simons (1938–2024)](https://funkfolio.com/gurus/jim-simons) 0.2% / 0.3%

#### Elevance Health only (16)

- [Seth Klarman](https://funkfolio.com/gurus/seth-klarman) 9.8%
- [Sequoia Fund team](https://funkfolio.com/gurus/sequoia-fund) 6.2%
- [Glenn Greenberg](https://funkfolio.com/gurus/glenn-greenberg) 5.2%
- [Matthew McLennan](https://funkfolio.com/gurus/first-eagle) 2.6%
- [Bill Nygren](https://funkfolio.com/gurus/bill-nygren) 2.5%
- [Lew Sanders](https://funkfolio.com/gurus/lew-sanders) 2.2%
- [C.T. Fitzpatrick](https://funkfolio.com/gurus/ct-fitzpatrick) 1.7%
- [Stephen Yacktman](https://funkfolio.com/gurus/stephen-yacktman) 1.6%
- [Anthony Bozza](https://funkfolio.com/gurus/anthony-bozza) 1.2%
- [Diamond Hill team](https://funkfolio.com/gurus/diamond-hill) 0.9%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.5%
- [Baillie Gifford team](https://funkfolio.com/gurus/baillie-gifford) 0.4%
- [Richard Pzena](https://funkfolio.com/gurus/richard-pzena) 0.3%
- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.2%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.2%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.2%

#### Regeneron Pharmaceuticals only (7)

- [Mason Hawkins](https://funkfolio.com/gurus/mason-hawkins) 5.0%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 1.9%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.5%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 0.3%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.2%
- [Joel Greenblatt](https://funkfolio.com/gurus/joel-greenblatt) 0.2%
- [Ray Dalio (founder)](https://funkfolio.com/gurus/bridgewater) 0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Elevance Health / Regeneron Pharmaceuticals). [Who owns ELV](https://funkfolio.com/stock/ELV/superinvestors) · [Who owns REGN](https://funkfolio.com/stock/REGN/superinvestors)

### More on Elevance Health

- [Elevance Health (ELV) stock page](https://funkfolio.com/stock/ELV)
- [Elevance Health market cap](https://funkfolio.com/stock/ELV/market-cap)
- [Elevance Health revenue](https://funkfolio.com/stock/ELV/revenue)
- [Elevance Health P/E ratio](https://funkfolio.com/stock/ELV/pe-ratio)
- [Elevance Health operating margin](https://funkfolio.com/stock/ELV/operating-margin)
- [Elevance Health total debt](https://funkfolio.com/stock/ELV/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Regeneron Pharmaceuticals

- [Regeneron Pharmaceuticals (REGN) stock page](https://funkfolio.com/stock/REGN)
- [Regeneron Pharmaceuticals market cap](https://funkfolio.com/stock/REGN/market-cap)
- [Regeneron Pharmaceuticals revenue](https://funkfolio.com/stock/REGN/revenue)
- [Regeneron Pharmaceuticals P/E ratio](https://funkfolio.com/stock/REGN/pe-ratio)
- [Regeneron Pharmaceuticals operating margin](https://funkfolio.com/stock/REGN/operating-margin)
- [Regeneron Pharmaceuticals total debt](https://funkfolio.com/stock/REGN/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Elevance Health against its closest peers

- [Elevance Health vs Cigna Group](https://funkfolio.com/compare/ci-vs-elv)
- [Elevance Health vs GSK](https://funkfolio.com/compare/elv-vs-gsk)
- [Elevance Health vs HCA Healthcare](https://funkfolio.com/compare/elv-vs-hca)

#### Regeneron Pharmaceuticals against its closest peers

- [Regeneron Pharmaceuticals vs GSK](https://funkfolio.com/compare/gsk-vs-regn)
- [Regeneron Pharmaceuticals vs HCA Healthcare](https://funkfolio.com/compare/hca-vs-regn)
- [Regeneron Pharmaceuticals vs CVS Health](https://funkfolio.com/compare/cvs-vs-regn)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Elevance Health or Regeneron Pharmaceuticals?**

By market value, Regeneron Pharmaceuticals is the larger: $99.1B against $93.8B for Elevance Health. By revenue in its latest fiscal year, Elevance Health is the larger: $199.1B against $14.3B for Regeneron Pharmaceuticals.

**Which has the higher P/E ratio?**

Regeneron Pharmaceuticals: 21.2, against 18.4 for Elevance Health. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Regeneron Pharmaceuticals: 24.9%, against 3.62% for Elevance Health. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has the higher dividend yield?**

Elevance Health: 1.54%, against 0.39% for Regeneron Pharmaceuticals. Dividend yield is the last twelve months' dividends as a share of today's share price.

**Which has more debt?**

Elevance Health: $32B, against $2B for Regeneron Pharmaceuticals. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Elevance Health and Regeneron Pharmaceuticals?**

In their latest 13F filings, Harry Burn, Jeremy Grantham (co-founder) and Jim Simons (1938–2024) hold both.

### Cite this page

Funkfolio, “Elevance Health vs Regeneron Pharmaceuticals”, data as of 18 November 2026. https://funkfolio.com/compare/elv-vs-regn

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
